Pfizer Inc. Archives - PharmaDeviceNews

Pfizer’s positive Phase 3 LITFULO results in nonsegmental vitiligo have strengthened the treatment’s global regulatory prospects, while detailed efficacy, safety and durability data remain key to its clinical and commercial outlook. Representative image.

Pfizer’s LITFULO cleared a major Phase 3 hurdle in vitiligo, but the missing numbers could decide its future

by Pallavi Madhiraju
August 2, 2026
0 Comments

Pfizer’s Phase 3 LITFULO vitiligo results strengthen its filing case, but dose, safety and durability details remain decisive.

Representative image: Corporate and clinical teams review melanoma trial data as Scancell moves to acquire Neuphoria Therapeutics $NEUP and secure up to $89 million to fund the Phase 3 iSCIB1+ immunotherapy program.

Pharma & Biotech

Scancell secures path to $89m financing through Neuphoria Therapeutics merger

by Soujanya Ravi
July 23, 2026
0 Comments

Scancell will acquire Neuphoria Therapeutics and pursue up to $89 million to fund the Phase 3 iSCIB1+ melanoma trial through 2028.

FDA approval of Keytruda and Keytruda Qlex with Padcev expands perioperative treatment options for adults with muscle-invasive bladder cancer. Representative image.

Pharma & Biotech

Can Keytruda plus Padcev replace cisplatin chemotherapy before bladder cancer surgery?

by Pallavi Madhiraju
July 11, 2026
0 Comments

FDA approval moves Keytruda and Padcev into perioperative MIBC regardless of cisplatin eligibility, intensifying the contest for standard care.

FDA approval of Padcev plus Keytruda expands perioperative treatment options for adults with muscle-invasive bladder cancer regardless of cisplatin eligibility. Representative image.

Pharma & Biotech

Pfizer and Astellas secure wider FDA label for Padcev plus Keytruda in muscle-invasive bladder cancer

by Pallavi Madhiraju
July 11, 2026
0 Comments

FDA expands Padcev plus Keytruda to adults with muscle-invasive bladder cancer regardless of cisplatin eligibility, reshaping perioperative care.

Pharma & Biotech

Lupin’s tentative FDA approval for enzalutamide sets up a high-value generic challenge to Xtandi

by Pallavi Madhiraju
June 29, 2026
0 Comments

Lupin Limited has moved closer to the United States enzalutamide market with proposed 120 mg and 160 mg tablets that could reduce pill burden. Patent timing, final approval, market access and competition will determine whether that formulation advantage becomes commercially meaningful.

Representative image: Pfizer’s Ibrance approval introduces a new frontline maintenance option for HR-positive, HER2-positive metastatic breast cancer following induction therapy.

Pharma & Biotech

Pfizer’s Ibrance wins broader FDA role as metastatic breast cancer treatment becomes more complex

by Pallavi Madhiraju
June 28, 2026
0 Comments

The FDA approval brings CDK4/6 inhibition into HR-positive, HER2-positive metastatic breast cancer maintenance, although toxicity, immature survival data and a rapidly changing first-line market could shape adoption.